GLG News by Oncology Reimbursement Experts (US)

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New Agents in Melanoma Show Advances at ASCO

June 9, 2011

Drugs Show Promise Slowing Advanced Melanoma | www.nytimes.com

Data presented a the ASCO meeting showed an overall survival benefit for patients receiving Roche/Genentech's vemurafenib and Bristol-Myers Squibb/s Yervoy (ipilimumab) when these agents were compared to standard of care therapy.

Bruce Goldberg, Pharmacist

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Rx Savings with Generic vs Branded Medications

March 28, 2011

Buying Brand-Name Drugs Over Generics Raises Medicaid Costs | www.bloomberg.com

With dollar shortfalls for Rx benefits, controlling drug costs is imperative. By utilizing a strict formulary of covered products, along with clear, real time messaging to the pharmacies,  the generic fill rate (GFR) will rise. With a higher GFR, savings is attained.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Long term Revlimid (Celgene) may cause cancer.

December 7, 2010

Celgene shares plummet on Revlimid malignancy data | www.reuters.com

Data presented at the American Society of Hematology Convention suggests the possibility that long term use of Revlimid may be a associated with the development of secondary malignancies.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Outlook is better for Provenge

November 20, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

A Medicare advisory panel gave a lukewarm endorsement to Provenge. Final Medicare opinion is pending.

David Zimmerman, President/Owner

David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

CVS vs. Walgreen's and the latest....

June 12, 2010

As a consultant and clinical pharmacist with over 30 years experience, I am glad someone.... and in this case... Walgreen's finally woke up to fees that are insulting low and a losing proposition. It has been well established the the "average expense to dispense a prescription" (the pharmacy's actual costs including rent, payroll, overhead, etc) is in the $10 range per prescription. Why would any pharmacy sign a contract with a fee of $1.50 per prescription?

Bruce Goldberg, Pharmacist

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Lupin's opportunity to drop the Lotrel margin!

February 15, 2010

Lupin gets US FDA approval for hypertension capsules | www.pharmabiz.com

The approval of Lupin's generic Lotrel line will create one more player in a field that is currently not very crowded. Yet, don't expect the other players to not react! Generic Lotrel is currently priced relatively high compared to other multi-source hypertensive products.

Bruce Goldberg, Pharmacist

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Cetirizine OTC liquid. A day late and a dollar short.

February 8, 2010

Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC) | www.pipelinereview.com

Why the delay? Teva, Taro, and Perrigo all have strong footholds in this market. Rx and OTC competition remains strong, thus what would allow a new player to grow quickly outside of eroding the price market?

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Algeta Begins Enrolling Patients in Prostate Cancer Study

December 21, 2009

Algeta begins phase-III trial of Alpharadin in male patient with castration-resistant prostate cancer | www.pharmabiz.com

The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study is a double-blind, randomized, controlled trial that enrols patients to be randomized to receive Alpharadin (radium-223 chloride) plus best standard of care or placebo plus best standard of care.  Approximately 750 patients are expected to be enrolled in this multi-institution trial with. recruitment expected to be complete by the second half of 2010. The primary outcome to be measured is overall survival.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

An Overall Survival Benefit In Chronic Lymphocytic Leukemia (CLL)

December 10, 2009

Roche presents pivotal phase-III study of CLL8 at ASH 2009 | www.pharmabiz.com

The CLL8 Trial demonstrated that FCR (Fludarabine, Cyotxan, Rituxan) provided a modest, but statistically significant survival benefit over FC (Fludarabine, Cytoxan) in patients with chronic lymphocytic leukemia.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

CCL8 Data Coming to ASH

December 8, 2009

Roche to present CLL8's pivotal phase-III study results at ASH in New Orleans | www.pharmabiz.com

Updated results from the CCL8 trial of Fludarabine and Cytoxan (FC) vs. Fludarabine, Cytoxan, and Rituxan (FCR) will be released at the American Society of Hematology Meeting (ASH) in New Orleans.

Page : 12345678910Next1 to 10 of 111

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News